We'll know more about the company's medium-term prospects by the end of the year.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $56.42, moving +1.58% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 1.05% for the ...

The Pairwise Fulcrum® platform includes proprietary gene editing tools, enzymes, and trait libraries that enable precise genetic changes, unlocking plants’ inherent potential and significantly ...

Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...

CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

Qatar has taken a landmark step in precision medicine after Sidra Medicine became the first hospital in the country — and one ...

Researchers have developed a modified CRISPR gene-editing tool with potential to silence the extra chromosome causing Down ...

Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...

A research team has discovered an enhanced CRISPR gene-editing system that could enable targeted delivery inside the human ...